{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-177015","form_type":"8-K","ticker":"PRGO","cik":"0001585364","company_name":"PERRIGO Co plc","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.653084+00:00","generated_at":"2026-05-31T22:08:01.439233+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M","bullets":["Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.","Proceeds to be redeployed for debt repayment; impact included in previously issued 2024 outlook.","Rare Diseases business had FY2023 net sales of ~€50M and adjusted EBITDA of ~€20M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-177015","json":"https://secwatch.observer/filing/0001193125-24-177015.json","markdown":"https://secwatch.observer/filing/0001193125-24-177015.md","text":"https://secwatch.observer/filing/0001193125-24-177015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/0001193125-24-177015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/d846136d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:08:01.439233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}